Teva Pharmaceutical (TEVA) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (NASDAQ: TEVA) reported Q2 EPS of $1.10, $0.01 better than the analyst estimate of $1.09. Revenue for the quarter came in at $4.21 billion versus the consensus estimate of $4.24 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aurinia settles patent dispute with Teva over generic voclosporin
- Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
